Your browser doesn't support javascript.
loading
Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
Haralambieva, Iana H; Monroe, Jonathon M; Ovsyannikova, Inna G; Warner, Nathaniel D; Grill, Diane E; Poland, Gregory A; Kennedy, Richard B.
Afiliação
  • Haralambieva IH; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
  • Monroe JM; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
  • Ovsyannikova IG; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
  • Warner ND; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
  • Grill DE; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
  • Poland GA; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
  • Kennedy RB; Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States. Electronic address: kennedy.rick@mayo.edu.
Vaccine ; 42(4): 912-917, 2024 Feb 06.
Article em En | MEDLINE | ID: mdl-38233288
ABSTRACT
The responsiveness/cross-binding of vaccine-induced memory B cells/MBCs to previous and emerging divergent SARS-CoV-2 variants (e.g., Omicron) is understudied. In this longitudinal study subjects receiving two or three doses of monovalent ancestral strain-containing COVID-19 mRNA vaccine were evaluated. In contrast to others, we observed significantly lower frequencies of MBCs reactive to the receptor-binding domain/RBD, the N-terminal domain/NTD, and the S1 of Omicron/BA.1, compared to Wuhan and Delta, even after a 3rd vaccine dose/booster. Our study is a proof of concept that MBC cross-reactivity to variants with greater sequence divergence from the vaccine strain may be overestimated and suggests that these variants may exhibit immune escape with reduced recognition by circulating pre-existing MBCs upon infection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article